Lung Cancer

Fred R. Hirsch, MD, PhD, professor of Medicine, University of Colorado Denver, CEO, the International Association for the Study of Lung Cancer (IASLC), discusses the value of PD-L1 assays for patients with non–small cell lung cancer. Hirsch shared his during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

Harvey I. Pass, MD, director, Thoracic Surgery, Thoracic Oncology, NYU Langone Medical Center, discusses what it means to take a personalized approach to surgery in lung cancer.

Ceritinib improved progression-free survival compared with standard chemotherapy as a first-line treatment for patients with ALK-positive non–small cell lung cancer.

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the Lung Master Protocol (Lung-MAP) Trial and how it is an example of a rational clinical design that will impact patient care. Gandara shared this insight during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

James R. Jett, MD, professor of Medicine Emeritus, National Jewish Health, discusses the most frequent debates surrounding molecular testing for patients with lung cancer.

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the toxicity profile of the therapies used in the CheckMate-227 trial.

Naiyer Rizvi, MD, discusses pivotal clinical trials of immunotherapy agents for patients with lung cancer and expresses his optimism regarding the treatment for the field.

Although lung cancer remains the leading cause of cancer-related mortality in the United States and 5-year survival rates are low at 17.8%, the grim picture for this tumor type is starting to shift to a more hopeful one as its biology is becoming better understood, facilitating treatment selection and providing researchers with new therapeutic targets.

Jonathan Riess, MD, assistant professor of Medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses ROS1 fusions in lung cancer.

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses combination therapies in the treatment of patients with lung cancer.

James Stevenson, MD, medical oncologist at Cleveland Clinic, discusses the potential of immunotherapy agents as treatment for patients with squamous non–small cell lung cancer (NSCLC).

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses stereotactic body radiation therapy (SBRT) as a treatment for patients with lung cancer.

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab (Keytruda) as a first-line treatment for patients with PD-L1–positive non–small cell lung cancer.

John D. Minna, MD, who helped establish the first tumor lines and discover the c-Myc oncogene in lung cancer, was honored in the Lung Cancer category with a 2015 Giants of Cancer Care award, a program that OncLive launched to recognize leaders in the field.

The European Commission has approved crizotinib (Xalkori) as a treatment for patients with advanced ROS1-positive non–small cell lung cancer.

Atezolizumab (Tecentriq) improved survival compared with docetaxel in patients with advanced non–small cell lung cancer following the failure of platinum-based chemotherapy.

Nathan Pennell, MD, PhD, associate professor of Medicine at Cleveland Clinic, discusses the importance of testing patients with non–small cell lung cancer (NSCLC) to determine if they harbor the EGFR mutation, as well as the agents available to target that genetic abnormality.

A new drug application has been submitted for brigatinib (AP26113) as a potential treatment for patients with advanced ALK-positive non–small cell lung cancer following resistance or intolerance to crizotinib (Xalkori).

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the potential of immunotherapy combinations as treatment for patients with non–small cell lung cancer (NSCLC).